A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
Clinical trial NCT06110663 · UNKNOWN
Trial details
- NCT number
- NCT06110663
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-30
- Primary completion
- 2024-12-30
- Enrollment
- 314
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.